| Marrero Endocrinology And Metabolism Llc | |
|
11 Calle Ana Lens De Susoni Arecibo PR 00612 | |
| (787) 568-3573 | |
| Not Available |
| Full Name | Marrero Endocrinology And Metabolism Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 11 Calle Ana Lens De Susoni, Arecibo, Puerto Rico |
| Authorized Official Name and Position | Maria Del Carmen Marrero Mendez (SOLE PROPRIETOR) |
| Authorized Official Contact | 7873766384 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Marrero Endocrinology And Metabolism Llc Po Box 141591 Arecibo PR 00614-1591 Ph: (787) 568-3573 | Marrero Endocrinology And Metabolism Llc 11 Calle Ana Lens De Susoni Arecibo PR 00612 Ph: (787) 568-3573 |
| NPI Number | 1235724378 |
|---|---|
| Provider Enumeration Date | 03/01/2021 |
| Last Update Date | 12/24/2022 |
| Medicare PECOS PAC ID | 5496162091 |
|---|---|
| Medicare Enrollment ID | O20210326001361 |
News Archive
New research in The Journal of Physiology has found, using a mouse model, that microbes in the maternal intestine may contribute to impairment of the gut barrier during pregnancy.
GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Australia risks a serious swine flu (H1N1 influenza virus) outbreak with two-thirds (65 per cent) of unprotected Australians stating they're unlikely to get vaccinated against the disease in the next 12 months, according to an MBF Healthwatch Poll.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235724378 | NPI | - | NPPES |
| 19896 | Other | PR | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | (* (Not Available)) | Primary |
| Provider Name | Maria Del Carmen Marrero Mendez |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1659758324 PECOS PAC ID: 5698103570 Enrollment ID: I20200309001387 |
News Archive
New research in The Journal of Physiology has found, using a mouse model, that microbes in the maternal intestine may contribute to impairment of the gut barrier during pregnancy.
GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Australia risks a serious swine flu (H1N1 influenza virus) outbreak with two-thirds (65 per cent) of unprotected Australians stating they're unlikely to get vaccinated against the disease in the next 12 months, according to an MBF Healthwatch Poll.
› Verified 4 days ago
News Archive
New research in The Journal of Physiology has found, using a mouse model, that microbes in the maternal intestine may contribute to impairment of the gut barrier during pregnancy.
GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Australia risks a serious swine flu (H1N1 influenza virus) outbreak with two-thirds (65 per cent) of unprotected Australians stating they're unlikely to get vaccinated against the disease in the next 12 months, according to an MBF Healthwatch Poll.
› Verified 4 days ago
Consultorio Medico M L O Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Car 129 Km 37 H7 Bo Hato Arriba-denkton, Arecibo, PR 00612 Phone: 787-650-1353 Fax: 787-650-1353 | |
Cdt Villa Los Santos Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Urbanizacion Villa Los Santos, Calle 16 V-1, Arecibo, PR 00612 Phone: 787-879-1585 Fax: 787-879-4315 | |
Aor Family Medicine Consulting Services,llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: Hospital Pavia Arecibo, 619 Ave San Luis Complejo Oficinas Medicas 1er Piso, Arecibo, PR 00612 Phone: 787-650-7272 | |
Family Medicine Consultant Group Psc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 163 Ave. Antonio R. Barcelo, Arecibo Executive Hall, Arecibo, PR 00612 Phone: 787-879-3688 | |
Sala Emergencia Metropavia Clinic Arecibo Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Carr 129, Zona Industrial Victor Rojas Ii, Arecibo, PR 00612 Phone: 787-650-0020 Fax: 787-650-0099 | |
Centro De Tratamiento Primario Del Atlantico Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Carr. 123 Km. 73, Bo. Hato Viejo, Arecibo, PR 00612 Phone: 787-608-8047 | |
Villa Los Santos Clinic (v) Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: Villa Los Santos Calle 16 V 1, Arecibo, PR 00612 Phone: 787-879-1585 |